{"id":"W3203425821","doi":"10.51731/cjht.2021.168","title":"Nivolumab (Opdivo) in combination with Ipilimumab (Yervoy)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Ipilimumab; Nivolumab; Reimbursement; Medicine; Drug; Internal medicine; Oncology; Pharmacology; Immunotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003923918,0.0000876401,0.0003174767,0.0005387459,0.00008941129,0.0000194161,0.0001105068,0.0001054295,0.00005129968],"category_scores_gemma":[0.000161424,0.0000708558,0.00005086232,0.0006051282,0.0001477707,0.0000833371,0.000006629997,0.0003635103,0.000001776419],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007744959,"about_ca_system_score_gemma":0.005882937,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004362132,"about_ca_topic_score_gemma":0.03036197,"domain_scores_codex":[0.9989985,0.00003978107,0.0004113593,0.0001059009,0.0001423318,0.0003021339],"domain_scores_gemma":[0.9992991,0.00002407844,0.0002193319,0.0001884168,0.0002078795,0.00006119618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0004535278,0.0000885976,0.03606625,0.0001842391,0.00008648649,0.001569358,0.0004418863,0.0000053104,0.0004176584,0.0005065676,0.002921298,0.9572588],"study_design_scores_gemma":[0.02344381,0.006356794,0.5332507,0.003930782,0.00005855537,0.007971612,0.0250012,0.00003993224,0.008678913,0.003415911,0.3873743,0.0004774833],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8158344,0.08293431,0.0001437489,0.100031,0.000274637,0.0002276278,0.000005851451,0.00005299964,0.0004953778],"genre_scores_gemma":[0.9973105,0.001024871,0.0006521217,0.0008686843,0.000004480883,0.000003150844,0.00000343739,0.00001044407,0.0001223441],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9567813,"threshold_uncertainty_score":0.9997528,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02037484201940579,"score_gpt":0.2716369777010043,"score_spread":0.2512621356815985,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}